AKRO News and Press, Akero Therapeutics Inc. From 11/12/21

Akero Therapeutics (NASDAQ:AKRO): Q3 GAAP EPS of -$0.70 beats by $0.16. Cash, cash equivalents and short-term marketable securities for the period ended September 30, 2021 were $215.1M Press Release For further details see: Akero Therapeutics EPS beats by $0.16

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today reported third quarter financial results for the period end...

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management w...

Gainers: Green Plains Partners LP (NASDAQ:GPP) +8%. Akero Therapeutics AKRO +5%. Ramaco Resources (NASDAQ:METC) +4%. Mimecast Limited (NASDAQ:MIME) +3%. Liberty Global plc (NASDAQ:LBTYA) +3%. Losers: WD-40 Company WDFC -10%. Xiaobai Maimai (NASDAQ:HX) -4%. New Fortress Energy (...

SOUTH SAN FRANCISCO, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced that the U.S. Food and Drug Administration (FDA...

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced that Tim Rolph, Akero’s Chief Sc...

AKRO has continued delivering strong data from its phase 2a trial. Nearest major catalyst is HARMONY trial data in 3Q 2022. The company has a decent amount of cash. For further details see: Akero: Ticking All The Right Boxes In NASH

SOUTH SAN FRANCISCO, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced that members of the management team wi...

SOUTH SAN FRANCISCO, Calif., Aug. 13, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today reported second quarter financial results fo...

SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced the appointment of Yuan Xu, Ph.D., to its Board of Directors as an ...